Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Johnson & Johnson (NYSE: JNJ) | Delayed: 257.78 -1.58 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $259.36 | 52 Week High | $126.07 | |||
| Open | $257.50 | 52 Week Low | $94.28 | |||
| Day High | $257.80 | P/E | 53.59 | |||
| Day Low | $254.56 | EPS | $4.81 | |||
| Volume | 6,556,361 | |||||
